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(RRRs) in VTE events with rivaroxaban against enoxaparin of
70–79% (p < 0.001) following THR and 49% following TKR
(p < 0.001). However, the effect of rivaroxaban relative to alter-
native prophylaxes is also important, including those presently in
development. A systematic literature review identiﬁed RCTs
comparing enoxaparin with warfarin, fondaparinux or dabigat-
ran in THR or TKR. Indirect comparisons of rivaroxaban to
each were conducted, using enoxaparin as common comparator.
Whenever the comparison included more than three studies,
a meta-regression was performed. Results presented are RRRs
from those analyses. RESULTS: Rivaroxaban showed statisti-
cally signiﬁcant reductions in the incidence of key endpoints. In
THR, when compared with fondaparinux, rivaroxaban was
associated with RRRs of 56% in total VTE (p = 0.015) and 89%
(p = 0.015) in symptomatic VTE. When compared with dabiga-
tran, RRRs with rivaroxaban were 86% (p = 0.0018) in symp-
tomatic VTE and 77% (p < 0.001) in total VTE. Similarly, when
compared with warfarin, the RRR in symptomatic VTE with
rivaroxaban was 92% (p = 0.003). In TKR, rivaroxaban pro-
duced 67% (p < 0.001) and 66% (p < 0.001) reductions in total
VTE and deep vein thrombosis (DVT) respectively, versus war-
farin, and 50% (p < 0.001) reductions in total VTE and DVT
versus dabigatran. No other statistically signiﬁcant differences
were found. Importantly for a new anticoagulant, there were
no increases in major bleeding so safety endpoints are unlikely
to inﬂuence cost-effectiveness. CONCLUSION: Rivaroxaban
reduced the incidence of overall or symptomatic VTE events
relative to alternative prophylaxes without increased major
bleeding, reﬂecting a better clinical proﬁle. These risk reductions
may have implications for cost-effectiveness analyses.
PCV40
COST-EFFECTIVENESS ANALYSIS OF DRUG-ELUTING STENT
VS BARE METAL STENT IN PATIENTSWITH ISCHAEMIC
HEART DISEASE IN SOCIAL SECURITY MEXICAN INSTITUTE.
González-Díaz B1, Contreras-Hernandez I1, Salinas-Escudero G2,
Garduño-Espinosa J1,Arguero-Sànchez R3, Castaño-Guerra R3,
Farell-Campa J3
1Social Security Mexican Institute, Mexico City, Mexico, 2Hospital
Infantil de México Federico Gomez, Mexico City, Mexico, 3Hospital de
Cardiologia Centro Medico Nacional Siglo XXI, Mexico City, Mexico
OBJECTIVE: To estimate the cost-effectiveness of the use of
drug-eluting stent compared to bare-metal stent in a cohort of
patients with coronary disease in the Social Security Mexican
Institute (IMSS). METHODS: Cost-effectiveness in a cohort of
patients with ischemic disease with indication of PCI (Percuta-
neous Coronary Intervention). The measure of effectiveness was
the rate of clinical success without major cardiovascular adverse
events. The cost and effectiveness of the treatment were
obtained from clinical follow-up of the cohort from 104
patients in the Cardiology Hospital of IMSS. The micro-costing
technique was used, and the costs come from bases institutional
costs. The results are expressed in US dollars (US$) in 2007.
Given the time horizon of the study (12 months), the discount
rate was not applie. We performed a sensitivity analysis proba-
bilistic, and I think the curve of acceptability. RESULTS: The
61.5% of patients in the cohort used bare-metal stent and
38.5% drug-eluting stent, drug-eluting stent showed the highest
average cost per patient US$15,452.9  12,996.8 compared
with bare-metal stent US$14,254.4  10,826.5. However, the
effectiveness drug-eluting stent found were 97.44% (95%
92.48–100) regarding a bare-metal stent 81.67% (95% CI
71.88–91.46). The RCE was US$17,453.5 in the case of drug-
eluting stent and US$15,829.6 with bare-metal stent, the RCEI
was US$7419. The acceptability curve shows that the treatment
of drug-eluting stent becomes the dominant cost-effectiveness
alternative from WTP US$15,109.9. The probabilistic analysis
shows that drug-eluting stent is more cost effective when it
exceeds US$21,153.8 WTP per patient. CONCLUSION: Drug-
eluting stent is an alternative treatment interventional revascu-
larization with better outcomes in health, and depending from
the availability to pay can be a cost-effectiveness alternative to
the institution.
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OBJECTIVE: To consider the cost-effectiveness of POM statins,
OTC statin and plant sterol/stanol products from the perspective
of middle aged males when used according to current UK guid-
ance for the primary prevention of CVD. METHODS: We used
a Markov-Model to obtain the outcomes for an illustrative
cohort up to 100 years old or death, whichever come sooner. For
the base-case we assumed that all would receive POM statins
from 70 years old and all had to pay for their prescription charge
up to 59 years. The main outcomes for effects were QALYs
(quality-adjusted life-years) and LYG (Life Years Gained). The
main costs included were prescription charges, product costs,
travel costs and gross weekly incomes. The NICE technology
assessment report “Statins for the Prevention of Coronary
Events” published in 2005 was used for transition probabilities
and utility values. Updated costs for 2007 values extracted from
NHS and “HM Revenue & Customs” databases, and average
retail prices of the UK market. RESULTS: Estimated discounted
incremental cost/QALYs were 2970.63, 8026.37 and
16,536.84 for POM statins, OTC statin and plant stanol/sterol
products, respectively. Estimated discounted incremental cost/
LYGs were 5339.02, 14,458.69 and 30,076.96, respec-
tively. Cost/QALYs ranged from 1318.03 to 7854.44,
4289.46 to 11,763.28 and 3961.10 to 29,112.59 for
POM statins, OTC statin and plant sterol/stanol products,
respectively in the univariate sensitivity analyses. CONCLU-
SION: From the patient’s viewpoint, the most cost-effective
intervention is a POM statin (2970.63/QALY). There are con-
siderable differences between the most (POM statins) and the
least (plant sterol/stanol products) cost-effective interventions.
However, for individual patients non-eligibility for free prescrip-
tion or a strong desire to avoid medicalising disease prevention
may overturn the main results.
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OBJECTIVE: To study preventive technologies economic efﬁ-
ciency for patients with cardiovascular diseases in Russia.
METHODS: The study consisted of two parts. The ﬁrst part
involved 303 hypertensive patients without serious s complica-
tions. The second part involved 100 patients with coronary heart
disease (CHD). In both substudies, patients were randomized to
treatment and control groups. Patients of the treatment group
participated in a structured education program for hypertensive
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patients or for patients with CHD, and patients of control group
were in routine clinical practice. All patients were observed
during 12 months. Economic efﬁciency in both cases was evalu-
ated on the basis of “cost of illness” and “cost-effectiveness”
analysis. RESULTS: In hypertensive patients we received the
following results. The cost-efﬁciency ratio for decreasing blood
pressure on 1% was $216.6 in the treatment group and $1179 in
the control group. The results of patients’ education in CHD
patient were the following: The cost-efﬁciency ratio for decreas-
ing angina attacks frequency on 1% was S974 in treatment group
and 2838$ in control group. The cost-efﬁciency ratio for decreas-
ing cholesterol on 1% was $2857 in the treatment group and
S4365 in the control group. The cost-efﬁciency ratio for decreas-
ing blood pressure on 1% was $1606 in the treatment group and
$9316 in the control group. CONCLUSION: Educational pre-
ventive technologies for patients with cardiovascular diseases are
cost-effective over a one-year period.
PCV43
OPTIMIZATION OF DIAGNOSIS ANDTREATMENT OF
CORONARY ARTERY DISEASE IN CHINAWITH USE OF
CORONARY CT ANGIOGRAPHY
Cheng M1, Hu S2, Lu B2, Higashi MK3, Marelli C4, Li J5,Veenstra DL1
1University of Washington, Seattle,WA, USA, 2Fuwai Hospital for
Cardiovascular Disease, Chinese Academy of Medical Sciences, Beijing,
Xicheng District, China, 3GE Healthcare,Wauwatosa,WI, USA,
4GE Healthcare, Buckinghamshire, UK, 5GE Healthcare, Beijing, China
OBJECTIVE: Diagnosis of coronary artery disease (CAD) in
China using coronary angiography (CA) is challenging due to
high disease prevalence and limited resources. It has been esti-
mated that up to 50% of Chinese patients are negative for CAD
upon CA. Coronary CT Angiography (CTA) may provide an
opportunity to minimize unnecessary invasive diagnostic proce-
dures and increase patient access to diagnosis of CAD in a
cost-effective manner. This study was conducted to evaluate the
potential costs and efﬁciency of utilizing CTA in combination
with CA to optimize diagnosis and care of patients with sus-
pected CAD in China. METHODS: We conducted a cost-
consequences analysis from the perspective of Fuwai Hospital in
Beijing. We developed a decision-analytic model comparing a
diagnostic strategy of CA only with a strategy of CTA in com-
bination with CA for patients with low to moderate pre-test
probability (based on Duke Clinical Score) of signiﬁcant disease.
All CA-positive patients were assumed to receive percutaneous
coronary intervention (PCI). CTA diagnostic accuracy data and
cost estimates were obtained from Fuwai Hospital and other
inputs were derived from the published literature. RESULTS: In
the base-case analysis, assuming a CAD prevalence of 39%
(range 18–64%) in the low to moderate risk patient population,
utilization of CTA in combination with CA lead to a cost savings
of $559 (USD) per patient (range $680–$416) compared to the
CA only diagnosis strategy. The hospital cost per diagnosis of
CAD was $12,483 (CTA + CA) (range $14,197–$11,900) and
$13,418 (CA only) (range $17,406–$12,100), and the propor-
tion of catheter lab diagnoses leading to PCI increased from 39%
(range 18–64%) to 73% (range 48–88%). CONCLUSION: Our
study suggests that CTA implementation in China could optimize
the patient population that undergoes invasive CA procedures
and provide cost-savings for Chinese hospitals.
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OBJECTIVE: To examine how found ‘obesity paradox’—a para-
doxical decrease in morbidity and mortality with increasing BMI
in subjects with cardiovascular disease (CVD)—relates to health
care-expenditures using Medical Expenditure Panel Survey
(MEPS). METHODS: We performed cross-sectional analyses of
11,385 adults from the 2005 MEPS, a national survey of nonin-
stitutionalized civilian population in the United States. Subjects
with CVD (coronary heart disease, myocardial infarction, stroke,
and hypertension) were determined from self-reports. Mean
expenditures per capita were estimated for NIH BMI categories
(under, normal, overweight, obese I, II, and III) using a two-part
exponential conditional model (ECM) adjusted for age, race,
wage, occupation, type of health insurance, degree level, and
smoking status. The ﬁrst part of the model was logistic regression
to predict the probability of incurring any expenditures. For the
second part, we used ECM since the log-scale expenditure data
was not leptokurtotic and was heteroscedastic. We performed
Box-Cox test and Park test to ﬁnd the link function and distri-
bution family. Average expenditures in 2005 U.S. dollars were
calculated by multiplying each person’s probability of incurring
any expense and expenditures. RESULTS: About 67% of sub-
jects with CVD (N = 2596) and 65% of subjects without CVD
(N = 8789) were overweight or obese. Using gamma distribution
with log link function, mean expenditures in CVD-group by BMI
categories were $3247, $3040, $3098, $2966, $3500, and $3375
(p = non-signiﬁcant). Those in subjects without CVD were
$1857, $2327, $2389, $2534, $3179, and $3783 (p < 0.001).
Age, smoking status, and Medicare were associated with
expenditures in CVD-group. CONCLUSION: Health care-
expenditures did not signiﬁcantly differ among BMI categories in
subjects with CVD whereas health care-expenditures were
increasing with BMI in subjects without CVD. This could be due
to the inﬂuence of CVD-care costs across weight categories in
CVD-group. We did not ﬁnd a obesity paradox in health care-
expenditures in subjects with CVD.
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OBJECTIVE: Few cost-of-illness studies in stroke have examined
the incremental impact of comorbid condition(s). The aim of this
study was to assess the costs of stroke management attributable
to stroke and comorbid conditions using data from the Medicare
program in the United States (U.S.). METHODS: Medicare
beneﬁciaries diagnosed with hemorrhagic (HS) and ischemic (IS)
stroke from 2002–2005 were identiﬁed from a 5% random
sample of Medicare outcomes and care database. Direct costs
were assessed from the perspective of the Medicare program.
Descriptive and multivariate analyses were performed. Data were
analyzed from one year prior to the index event through four
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